Nina Bhardwaj, MD, PhD, holds the Ward-Coleman chair in cancer research and is a professor of medicine, hematology, and oncology at the Icahn School of Medicine at Mount Sinai. Dr. Bhardwaj, director of immunotherapy at The Tisch Cancer Institute, is an immunologist who has made seminal contributions to human dendritic cell biology, specifically with respect to their isolation, subset discovery, immunobiology, antigen presenting function, and use as vaccine adjuvants in humans. Dr. Bhardwaj brings expertise in human immunology and a variety of immune therapies, having developed toll-like receptor (TLR) agonist- and dendritic cell-based vaccines for the treatment of both cancer and infection in several investigator-initiated studies, and, more recently, introduction of neoantigen vaccines into the clinic. Dr. Bhardwaj is also the founder and medical director of the Vaccine and Cell Therapy Lab at the Icahn School of Medicine at Mount Sinai, the first enterprise of its kind in the New York region. Dr. Bhardwaj has attracted multiple federal and foundation grants and has authored over 250 publications.